December 7, 2017 02:28 PM EST
Peer Review

Daniel Swish­er leaves an ail­ing Sune­sis and swoops in to lead Jazz Phar­ma­ceu­ti­cals

Brittany Meiling

Daniel Swish­er, the CEO of the strug­gling Sune­sis Phar­ma­ceu­ti­cals, has been re­cruit­ed to glob­al bio­phar­ma Jazz Phar­ma­ceu­ti­cals as the com­pa­ny’s new pres­i­dent and chief op­er­a­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times